Pharmaceuticals Global On demand · 24-48h

Global C-C Chemokine Receptor Type 5 Market Strategic Research Report

Global C-C Chemokine Receptor Type 5 Market Strategic Resear…
$3,500 USD
Market Research Reports
Strategic Research Report
Global C-C Chemokine Receptor Type 5 Market
$1.51B2025
9.9%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: BMS-813160, AG-1105, CCL-14, DS-001, Others

By Application: Infectious Diseases, Gastrointestinal Diseases, Immunology Research, Oncology, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: GSK ViiV Healthcare, Bristol Myers Squibb, CytoDyn, Addimmune, Thermo Fisher Scientific, Danaher Abcam, Becton Dickinson, Revvity BioLegend, Bio-Techne, Merck, Miltenyi Biotec, Eurofins Discovery, Cayman Chemical, MedChemExpress, Selleck Chemicals, TargetMol Chemicals, Tokyo Chemical Industry, Santa Cruz Biotechnology, OriGene Technologies, GeneTex, Proteintech, RayBiotech, MyBioSource, NSJ Bioreagents, eEnzyme, Sino Biological, ACROBiosystems, GenScript, CUSABIO, Elabscience, Bioss Antibodies, Affinity Biosciences

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 206 pages
Market size 2025
$1.51B
Billion USD
Forecast CAGR
9.9%
2025-2032
Forecast 2032
$2.9B
Projected
Области
5
Asia Pacific · Latin America · MEA · Europe · North America

Обзор

Scope of the Report

The global C-C Chemokine Receptor Type 5 market size is predicted to grow from US$ 1,507 million in 2025 to US$ 2,923 million in 2032; it is expected to grow at a CAGR of 9.9% from 2026 to 2032.

C-C Chemokine Receptor Type 5 is a biopharmaceutical target and product category centered on a human immune-cell membrane receptor. In its natural form, it is a transmembrane protein mainly expressed on immune cells such as T cells, macrophages and dendritic cells. It binds inflammatory chemokines and participates in immune-cell trafficking, inflammatory signaling and the regulation of local immune microenvironments. It is not a conventional visible mechanical component; in commercial markets, it is supplied or developed as therapeutic drugs, investigational candidates, research antibodies, recombinant proteins, engineered cell lines, gene vectors, assay kits and drug-screening services.

Market opportunities are driven by the rising value of immunomodulatory targets, sustained demand for antiviral treatment, exploration of combination strategies in tumor immunology, and deeper mechanistic research in inflammation and fibrotic diseases. The commercial value of this topic is not limited to one therapeutic product. It also covers antibodies, recombinant proteins, engineered cell lines, functional screening tools, pharmacology evaluation systems and preclinical research services. As drug-discovery platforms rely increasingly on cell-based functional assays, flow-cytometry analysis and target validation, demand for high-quality, batch-consistent and traceable products related to this target is expected to remain resilient.

Key Questions Addressed in this Report

What is the 10-year outlook for the global C-C Chemokine Receptor Type 5 market?

What factors are driving C-C Chemokine Receptor Type 5 market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do C-C Chemokine Receptor Type 5 market opportunities vary by end market size?

How does C-C Chemokine Receptor Type 5 break out by Type, by Application?

This report presents a comprehensive overview of the global C-C Chemokine Receptor Type 5 market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • BMS-813160
  • AG-1105
  • CCL-14
  • DS-001
  • Others

Segment by Commercial Delivery Form

  • Therapeutic Products
  • Research Reagents
  • Assay and Cell-Line Products
  • Others

Segment by Molecular Modality

  • Small-Molecule Antagonists
  • Antibody Products
  • Recombinant Protein & Gene Products
  • Others

Segment by Production Technology

  • Chemical Synthesis Products
  • Cell Expression Products
  • Antibody Production Products
  • Others

Segment by Application

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global C-C Chemokine Receptor Type 5 market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Infectious Diseases, Gastrointestinal Diseases, Immunology Research evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global C-C Chemokine Receptor Type 5 Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 9.9%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.51B
2025
Forecast
$2.9B
2032
CAGR
9.9%
2025–2032
Области
5
global
Key companies
GSK ViiV HealthcareBristol Myers SquibbCytoDynAddimmuneThermo Fisher ScientificDanaher AbcamBecton DickinsonRevvity BioLegend
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
BMS-813160AG-1105CCL-14DS-001Others
By Application
Infectious DiseasesGastrointestinal DiseasesImmunology ResearchOncologyOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 BMS-813160
  • 3.1.3 AG-1105
  • 3.1.4 CCL-14
  • 3.1.5 DS-001
  • 3.1.6 Others
  • 3.1.7 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Infectious Diseases
  • 4.1.3 Gastrointestinal Diseases
  • 4.1.4 Immunology Research
  • 4.1.5 Oncology
  • 4.1.6 Others
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 GSK ViiV Healthcare
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Bristol Myers Squibb
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 CytoDyn
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Addimmune
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Thermo Fisher Scientific
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Danaher Abcam
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Becton Dickinson
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Revvity BioLegend
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Bio-Techne
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Merck
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Miltenyi Biotec
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Eurofins Discovery
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Cayman Chemical
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 MedChemExpress
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Selleck Chemicals
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 TargetMol Chemicals
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Tokyo Chemical Industry
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Santa Cruz Biotechnology
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 OriGene Technologies
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 GeneTex
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Proteintech
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 RayBiotech
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 MyBioSource
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 NSJ Bioreagents
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 eEnzyme
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
  • 8.26 Sino Biological
  • 8.26.1 Company Overview
  • 8.26.2 Key Products & Segments
  • 8.26.3 Financial Performance (2023–2025)
  • 8.26.4 Business Strategy
  • 8.26.5 SWOT Analysis
  • 8.26.6 Strategic Implications (2026–2032)
  • 8.27 ACROBiosystems
  • 8.27.1 Company Overview
  • 8.27.2 Key Products & Segments
  • 8.27.3 Financial Performance (2023–2025)
  • 8.27.4 Business Strategy
  • 8.27.5 SWOT Analysis
  • 8.27.6 Strategic Implications (2026–2032)
  • 8.28 GenScript
  • 8.28.1 Company Overview
  • 8.28.2 Key Products & Segments
  • 8.28.3 Financial Performance (2023–2025)
  • 8.28.4 Business Strategy
  • 8.28.5 SWOT Analysis
  • 8.28.6 Strategic Implications (2026–2032)
  • 8.29 CUSABIO
  • 8.29.1 Company Overview
  • 8.29.2 Key Products & Segments
  • 8.29.3 Financial Performance (2023–2025)
  • 8.29.4 Business Strategy
  • 8.29.5 SWOT Analysis
  • 8.29.6 Strategic Implications (2026–2032)
  • 8.30 Elabscience
  • 8.30.1 Company Overview
  • 8.30.2 Key Products & Segments
  • 8.30.3 Financial Performance (2023–2025)
  • 8.30.4 Business Strategy
  • 8.30.5 SWOT Analysis
  • 8.30.6 Strategic Implications (2026–2032)
  • 8.31 Bioss Antibodies
  • 8.31.1 Company Overview
  • 8.31.2 Key Products & Segments
  • 8.31.3 Financial Performance (2023–2025)
  • 8.31.4 Business Strategy
  • 8.31.5 SWOT Analysis
  • 8.31.6 Strategic Implications (2026–2032)
  • 8.32 Affinity Biosciences
  • 8.32.1 Company Overview
  • 8.32.2 Key Products & Segments
  • 8.32.3 Financial Performance (2023–2025)
  • 8.32.4 Business Strategy
  • 8.32.5 SWOT Analysis
  • 8.32.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global C-C Chemokine Receptor Type 5 market?
The global C-C Chemokine Receptor Type 5 market is estimated at US$ 1.51 billion in 2025 (base year) and is projected to reach US$ 2.92 billion by 2032.
What is the forecast CAGR for the C-C Chemokine Receptor Type 5 market?
The market is expected to grow at a CAGR of 9.9% from 2026 to 2032, expanding from US$ 1.51 billion in 2025 to US$ 2.92 billion in 2032, roughly 1.9 times its base-year value.
What is C-C Chemokine Receptor Type 5?
C-C Chemokine Receptor Type 5 is a biopharmaceutical target and product category centered on a human immune-cell membrane receptor. In its natural form, it is a transmembrane protein mainly expressed on immune cells such as T cells, macrophages and dendritic cells. It binds inflammatory chemokines and participates in immune-cell trafficking, inflammatory signaling and the regulation of local immune microenvironments.
What are the main segments of the C-C Chemokine Receptor Type 5 market by type?
By type, the market is segmented into BMS-813160, AG-1105, CCL-14, DS-001 and Others.
Which applications drive demand in the C-C Chemokine Receptor Type 5 market?
Key applications covered include Infectious Diseases, Gastrointestinal Diseases, Immunology Research, Oncology and Others.
Who are the key players in the C-C Chemokine Receptor Type 5 market?
Key players profiled include GSK ViiV Healthcare, Bristol Myers Squibb, CytoDyn, Addimmune, Thermo Fisher Scientific, Danaher Abcam, Becton Dickinson and Revvity BioLegend, among 32 companies covered in total.
Which regions and countries are covered for C-C Chemokine Receptor Type 5?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the C-C Chemokine Receptor Type 5 market?
Market opportunities are driven by the rising value of immunomodulatory targets, sustained demand for antiviral treatment, exploration of combination strategies in tumor immunology, and deeper mechanistic research in inflammation and fibrotic diseases.
Who should buy the C-C Chemokine Receptor Type 5 market report?
The report is intended for manufacturers and solution providers, distributors and end users in Infectious Diseases, Gastrointestinal Diseases and Immunology Research, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the C-C Chemokine Receptor Type 5 market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3 500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.